James Hoyes provides strategic direction to the ENDECE leadership team as the firm moves its pipeline through the clinical development process and works to optimally position the pipeline products for commercialization. ENDECE products are built on a very strong foundation of exciting science and will be well positioned for both launch success and life cycle management across appropriate indications in order to meet unmet medical needs in the neuroscience arena. Jim brings senior executive experience to the ENDECE team having spent 30 years in the biopharma industry at EMD Serono, where he was President and Head of US Operations; and at Elan, Sanofi and Sterling Winthrop, where he held various senior management positions across various commercial and therapeutic area functions. In his career, Jim has gained deep experience in the CNS therapeutic area including extensive work in multiple sclerosis market. Jim also brings several years of strategic consulting experience as an Executive Partner at RxC International to ENDECE as well as insights gained as a past Board Member at PhRMA, BIO and MassBIO. Jim holds a B.S. in Biology from the Pennsylvania State University and has completed numerous executive management programs at leading business management schools such as MIT-Sloan School of Management, Thunderbird-The Garvin School of Management, Kellogg Graduate School of Management, Hong Kong University of Science and Technology, and INSEAD.

Jim is a skilled physician and highly accomplished senior pharmaceutical executive. Following a successful academic career, Jim has spent 25 years in the pharma and biotech industry, rising to the role of Chief Medical Officer. In recent years, Jim has served as a consultant and acting CMO for multiple pharma companies. Jim is Board Certified by the American Board of Psychiatry & Neurology and by the American Board of Sleep Medicine. He has been the recipient of multiple NIH grants and has authored more than 40 peer-reviewed scientific publications.

The focus of Jim’s experience in big pharma and biotech/specialty pharma has been in the CNS area, including clinical development programs for spinal cord injury/spasticity, pain, Alzheimer’s, schizophrenia, anxiety, ADHD, insomnia, narcolepsy, Parkinson’s, epilepsy and stuttering. Additionally, Jim has experience in more than a dozen other indications, including oncology and urology.

Jim has been a valued resource in support of investor relations, business development, alliance management and KOL cultivation. Jim has demonstrated a strong skill set in managing acquisitions, facilitating mergers, and assimilating firms being acquired in the pharmaceutical and biopharma fields.